Track topics on Twitter Track topics that are important to you
Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...
Cardiovascular risks were lower with colchicine use, in an observational study from a single medical center.
New questions have been raised about the validity and reliability of data in the ROCKET-AF trial, which serves as the backbone for the approval of rivaroxaban (Xarelto), according to an investigation ...
Colchicine use was associated with a 49% lower risk for cardiovascular events and a 73% reduction in all-cause mortality in patients with gout. Medscape Medical News
The warfarin arm of the ROCKET AF trial used a faulty INR device, leading to calls for independent verification of the study. Dr Mandrola agrees but is reassured by the real-world data on rivaroxa...
U.S. hospitals save money when they use the novel oral anticoagulant rivaroxaban instead of warfarin to treat patients with venous thromboembolism (VTE), a new analysis finds. Reuters Health Informa...
GI bleeding is a common complication of oral anticoagulation. How does the incidence of GI bleeding in AF patients taking rivaroxaban compare to those on warfarin? Journal of the American College of...
This case demonstrates that rivaroxaban can be an effective and safe therapeutic choice in the acute phase of pulmonary embolism, even in elderly patients. Journal of Medical Case Reports
Taking five or more meds is common in patients with AF, but for those taking fewer than that, the risk of bleeding was lower with rivaroxaban than with warfarin in the ROCKET-AF trial, suggests a new...
Colchicine is an anti-inflammatory drug that is used for a wide range of inflammatory diseases. Cardiovascular disease also has an inflammatory component but the effects of colchicine on cardiovascula...
Rivaroxaban is an anticoagulant prescribed for the management of atrial fibrillation. We describe a correlation between rivaroxaban and spontaneous vitreous hemorrhage.
Rivaroxaban is a factor-Xa-inhibitor which has been shown to be non-inferior to the vitamin-K-antagonist (VKA) warfarin in atrial fibrillation patients. In the manufacturer-sponsored trial, the rate o...
Four-factor prothrombin complex concentrate (PCC) 50 iu/kg is able to swiftly restore haemostatic parameters in healthy subjects on rivaroxaban. We hypothesized that lower dosages of PCC may be suffic...
Colchicine is a main alkaloid present in bitter and sweet variety of colchicum (Colchicum luteum Baker), which have been reported to possess anti-rheumatic, anti-gout, and anticancer potential. Colchi...